Objectives: In June 2011, the National Institute for Health and Care Excellence (NICE) Decision Support Unit published a Technical Support Document (TSD) providing recommendations on survival analysis for NICE technology appraisals (TAs). Survival analysis outputs are influential inputs into economic models estimating the cost-effectiveness of new cancer treatments. Hence, it is important that systematic and justifiable model selection approaches are used. This study investigates the extent to which the TSD recommendations have been followed since its publication. Methods: We reviewed NICE cancer TAs completed between July 2011 and July 2017. Information on survival analyses undertaken and associated critiques for overall survival (OS) a...
Background: Tumour response endpoints, such as overall response rate (ORR) and complete response (CR...
Objectives Partitioned survival models (PSMs) are routinely used to inform reimbursement decision...
Importance: There is a dearth of evidence examining the impact of newly licensed cancer medicines on...
Objectives Before an intervention is publicly funded within the United Kingdom, the cost-effectiv...
Objectives This research aims to explore how often the National Institute for Health and Care Excel...
Background The first histology-independent marketing authorisation in Europe was granted in 2019....
Background The first histology-independent marketing authorisation in Europe was granted in 2019. Th...
Objective: To assess whether using surrogate versus patient-relevant endpoints in pivotal trials of ...
Organizations that evaluate health technologies face significant challenges when dealing with uncert...
Objectives: A primary outcome in oncology trials is overall survival (OS). However, to estimate OS a...
Studies of clinical efficacy commonly report more than one clinical endpoint. For example, randomize...
The Evidence Review Group members that contributed to this editorial are funded by the UK NIHR HTA P...
BACKGROUND: The National Institute for Health and Care Excellence (NICE) commissioned a 'mock techno...
Objectives Dealing with uncertainty is one of the critical topics in health technology assessment. ...
INTRODUCTION: Due to the limitations of relying on randomised controlled trials, the potential benef...
Background: Tumour response endpoints, such as overall response rate (ORR) and complete response (CR...
Objectives Partitioned survival models (PSMs) are routinely used to inform reimbursement decision...
Importance: There is a dearth of evidence examining the impact of newly licensed cancer medicines on...
Objectives Before an intervention is publicly funded within the United Kingdom, the cost-effectiv...
Objectives This research aims to explore how often the National Institute for Health and Care Excel...
Background The first histology-independent marketing authorisation in Europe was granted in 2019....
Background The first histology-independent marketing authorisation in Europe was granted in 2019. Th...
Objective: To assess whether using surrogate versus patient-relevant endpoints in pivotal trials of ...
Organizations that evaluate health technologies face significant challenges when dealing with uncert...
Objectives: A primary outcome in oncology trials is overall survival (OS). However, to estimate OS a...
Studies of clinical efficacy commonly report more than one clinical endpoint. For example, randomize...
The Evidence Review Group members that contributed to this editorial are funded by the UK NIHR HTA P...
BACKGROUND: The National Institute for Health and Care Excellence (NICE) commissioned a 'mock techno...
Objectives Dealing with uncertainty is one of the critical topics in health technology assessment. ...
INTRODUCTION: Due to the limitations of relying on randomised controlled trials, the potential benef...
Background: Tumour response endpoints, such as overall response rate (ORR) and complete response (CR...
Objectives Partitioned survival models (PSMs) are routinely used to inform reimbursement decision...
Importance: There is a dearth of evidence examining the impact of newly licensed cancer medicines on...